Reply to H. Shojima et al.

Authors :: Absolom K
Warrington L
Hudson E
Hewison J
Holch P
Dawkins B
Hulme C
Brown J
Velikova G
Source :: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Aug 10; Vol. 39 (23), pp. 2633-2634. Date of Electronic Publication: 2021 May 12.
Publication Year :: 2021
Abstract: Competing Interests: Julia BrownResearch Funding: RocheOther Relationship: NIHR Galina VelikovaHonoraria: Eisai, Novartis, Pfizer, Roche UK, Seattle GeneticsConsulting or Advisory Role: Roche UK, Eisai, NovartisSpeakers' Bureau: NovartisResearch Funding: PfizerTravel, Accommodations, Expenses: Roche UK, Novartis, EisaiOther Relationship: University of LeedsNo other potential conflicts of interest were reported.

Language :: English
ISSN :: 1527-7755
Volume :: 39
Issue :: 23
Database :: MEDLINE
Journal :: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publication Type :: Report
Accession number :: 33979207
Full Text :: https://doi.org/10.1200/JCO.21.00684